- Ariad Pharmaceuticals (NASDAQ:ARIA) Q2 results: Total Revenues: $14.0M (+82.3%), Net Product Sales: $12.1M (+82.3%); Operating Expenses: $68.4M (-17.6%); Net Loss: ($56.9M) (+17.5%); Loss Per Share: ($0.30) (+18.9%); Quick Assets: $310.0M (+30.7%); Cash Burn: ($95.0M) (+16.7%).
- 2014 Guidance: Cash burn: ($175M - 165M); quick assets at year end: $230M - 235M; sufficient to fund operations into 2H 2016.